TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Thu Aug 27

NL

Article

TMFBiologyFool published an article 12:00 PM

The Duchenne Muscular Dystrophy Race Is On

Sarepta Therapeutics and BioMarin now have drugs under FDA review.

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 11:50 AM

Wed Aug 26

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 7:21 PM

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 12:22 PM

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 12:01 PM

Tue Aug 25

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 3:46 PM

Rule Breakers Boards Post

TMFBiologyFool posted to the Rule Breakers boards. 3:27 PM

Rule Breakers article.

TMFBiologyFool published an update. 1:42 PM

NL

Article

TMFBiologyFool published an article 1:16 PM

Why Shares of Celldex Therapeutics, Inc. Soared on Tuesday

This biotech is on a roller coaster that's not uncommon for the sector.

Fri Aug 21

One Boards Post

TMFBiologyFool replied to the One boards. 4:37 PM

Thu Aug 20

NL

Article

TMFBiologyFool published an article 8:40 PM

New Skin Cancer Drugs Delayed (but Investors and Patients Needn't Worry)

FDA decisions for Bristol-Myers Sqibb's Opdivo and Merck's Keytruda get pushed back.

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 6:18 PM

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 1:59 PM

Wed Aug 19

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 2:42 PM

Mon Aug 17

Stock Advisor Boards Post

TMFBiologyFool posted to the Stock Advisor boards. 1:08 PM

Pro Boards Post

TMFBiologyFool posted to the Pro boards. 1:07 PM

One Boards Post

TMFBiologyFool posted to the One boards. 12:53 PM

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 12:48 PM

Wed Aug 12

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 8:36 PM

NL

Article

TMFBiologyFool published an article 10:40 AM

Arena Pharmaceuticals' Belviq Sales Are Better Than They Appear (But They're Still Not Great)

Declining quarter-over-quarter sales look bad, but investors needn't freak out.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 96.78
Player Rank 2422 out of 75175
Score 1682.46
Score Change Today -66.47
Accuracy 66.67%
Active Picks 73
Total Picks 215
Best Pick ALKS (+358.10)
Worst Pick INCY (-1196.77)
Average Score per Pick 7.83
Charms Earned 9
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Big red star, 1000 posts CAPS All Star
Board Posts 1043
Recs Received 1218
People who have rec'd these posts 473
Recs to Posts Ratio (last 30 days) 3.30
Threads Started 110
Threads Started Percentage 10.55 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 50.05 %
Show TMFBiologyFool’s 10 Latest Posts